Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Matinas BioPharma Holdings Inc.’s current trading price is -83.48% away from its 52-week high, while its distance from the 52-week low is 33.27%. The stock’s price range during this period has varied between $0.11 and $0.89. The company, active in the Healthcare sector, saw a trading volume of around 0.74 million for the day, considerably higher average daily volume of 0.69 million observed over the last three months.
Matinas BioPharma Holdings Inc. (MTNB) currently has a stock price of $0.15. The stock saw a sharp increase in the last trading session, hitting a high of $0.15 after opening at $0.14. The lowest recorded price for the day was $0.14 before it closed at $0.13.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Matinas BioPharma Holdings Inc.’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $0.89 on 10/24/22, and the lowest price during the same period was recorded at $0.11 on 08/10/23.
How Financial Performance Impacts Market Capitalization
Matinas BioPharma Holdings Inc. (MTNB) has experienced a quarterly decline of -64.15% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 37.77M and boasts a workforce of 34 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.3487, with a change in price of -0.5130. Similarly, Matinas BioPharma Holdings Inc. recorded 612,181 in trading volume during the last 100 days, posting a change of -77.73%.
How MTNB’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for MTNB stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
MTNB Stock Stochastic Average
As of today, the raw stochastic average of Matinas BioPharma Holdings Inc. over the past 50 days is 11.85%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 20.94%. Additionally, the Stochastic %K and %D values for the company were 26.15% and 30.21%, respectively, over the past 20 days.
MTNB Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -70.60%.However, over the last six months, we can see a stronger performance of -62.21%. Over the last 30 days, the price of MTNB has leaped by -13.02%. And in the last five days, it has fallen by -6.13%.
